Skip to main content

Advertisement

SpringerLink
Log in

Quels marqueurs circulants pour quels cancers?

Which tumor markers for which cancers?

  • Dossier
  • Published:
BioTribune Magazine

Résumé

Le cancérologue dispose d’une large gamme de biomarqueurs circulants destinés à l’aider dans la prise en charge des patients dont il s’occupe. Nous revoyons ici les principaux marqueurs tumoraux selon leur nature et leurs principales indications tumorales (dépistage, diagnostic, pronostic et/ou marqueur de l’efficacité thérapeutique).

Abstract

Medical oncologists have a whole range of biomarkers at their disposal to help them care for their patients. We review the main tumor markers according to their nature and their indications (screening, diagnosis, prognosis and/or drug monitoring marker).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

/+/ Références

  1. Gold P, Freedman SO (1965). Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122(3): 467–81

    Article  PubMed  CAS  Google Scholar 

  2. Eche N, Pichon MF, Quillien V, et al. (2001). [Standards, options and recommendations for tumor markers in colorectal cancer]. Bull Cancer: 1177–206

  3. Voorzanger-Rousselot N, Garnero P (2007). Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. Cancer Treat Rev 33(3): 230–83

    Article  PubMed  CAS  Google Scholar 

  4. Locker GY, Hamilton S, Harris J et al. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33): 5313–27

    Article  PubMed  CAS  Google Scholar 

  5. Park YJ, Youk EG, Choi HS, et al. (1999). Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Colorectal Dis 14(2): 101–6

    Article  PubMed  Google Scholar 

  6. Renehan AG, Egger M, Saunders MP, et al. (2002). Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324(7341): 813

    Article  PubMed  Google Scholar 

  7. Basuyau JP, Blanc-Vincent MP, Bidart JM, et al. (2000). [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]. Bull Cancer 87(10): 723–37

    PubMed  CAS  Google Scholar 

  8. Arrigoni A, Andriulli A, Gindro T, et al. (1988). Pattern analysis of serum alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma in liver cirrhosis. Int J Biol Markers 3(3): 172–6

    PubMed  CAS  Google Scholar 

  9. Zhang BH, Yang BH, Tang ZY (2004). Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130(7): 417–22

    Article  PubMed  Google Scholar 

  10. Yao DF, Dong ZZ, Yao M (2007). Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 6(3): 241–7

    PubMed  CAS  Google Scholar 

  11. Jeng KS, Sheen IS, Tsai YC (2004). Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? Am J Gastroenterol 99(8): 1503–9

    Article  PubMed  Google Scholar 

  12. Mottet N, Berger N, Droz JP (2007). [Diagnosis and staging of germ-cell tumours of the testis]. Rev Prat 57(4): 365–78

    PubMed  Google Scholar 

  13. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers (2007). International Germ Cell Cancer Collaborative Group. J Clin Oncol 15(2): 594–603

    Google Scholar 

  14. Fizazi K, Culine S, Kramar A, et al. (2004). Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22(19): 3868–76

    Article  PubMed  Google Scholar 

  15. ESMO GUIDELINES Working Group (2007). ESMO clinical recommendations. Ann Oncol: 8(Suppl 2)

  16. Takada A, Ohmori K, Yoneda T, et al. (1993). Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53(2): 354–61

    PubMed  CAS  Google Scholar 

  17. Ziske C, Schlie C, Gorschluter M, et al. (2003). Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89(8): 1413–7

    Article  PubMed  CAS  Google Scholar 

  18. Rapkiewicz AV, Espina V, Petricoin EF, et al. (2004). Biomarkers of ovarian tumours. Eur J Cancer 40(17): 2604–12

    Article  PubMed  CAS  Google Scholar 

  19. Bast RC Jr,Badgwell D, Lu Z, et al. (2005). New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 Suppl 3: 274–81

    Article  PubMed  Google Scholar 

  20. Cannistra SA (2004). Cancer of the ovary. N Engl J Med 351(24): 2519–29

    Article  PubMed  CAS  Google Scholar 

  21. Paramasivam S, Tripcony L, Crandon A, et al. (2005). Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol 23(25): 5938–42

    Article  PubMed  CAS  Google Scholar 

  22. Riedinger JM, Bonnetain F, Basuyau JP, et al. (2007). Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 18(5): 881–5.

    Article  PubMed  CAS  Google Scholar 

  23. Stieber P, Hasholzner U, Bodenmuller H, et al. (1993). CYFRA 21-1. A new marker in lung cancer. Cancer 1993 72(3): 707–13

    Article  PubMed  CAS  Google Scholar 

  24. Nisman B, Lafair J, Heching N, et al. (1998). Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 82(10): 1850–9

    Article  PubMed  CAS  Google Scholar 

  25. Ebert W, Muley T, Drings P (1996). Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res (4B): 2161–8

  26. Reinmuth N, Brandt B, Semik M, et al. (2002). Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36(3): 265–70

    Article  PubMed  Google Scholar 

  27. Torre GC (1998). SCC antigen in malignant and nonmalignant squamous lesions. Tumour Biol 19(6): 517–26

    Article  PubMed  CAS  Google Scholar 

  28. Bonfrer JM, Schouwink JH, Korse CM, et al. (1997). Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 17(4B): 2971–3.

    PubMed  CAS  Google Scholar 

  29. Marcillac I, Troalen F, Bidart JM, et al. (1992). Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res 52(14): 3901–7

    PubMed  CAS  Google Scholar 

  30. Spencer CA, Wang CC (1995). Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 24(4): 841–63

    PubMed  CAS  Google Scholar 

  31. Harish K (2006). Thyroglobulin: current status in differentiated thyroid carcinoma (review). Endocr Regul 40(2): 53–67

    PubMed  CAS  Google Scholar 

  32. Eustatia-Rutten CF, Smit JW, Romijn JA, et al. (2004). Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61(1): 61–74

    Article  CAS  Google Scholar 

  33. Kaltsas GA, Besser GM, Grossman AB (2004). The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25(3): 458–511

    Article  PubMed  CAS  Google Scholar 

  34. D’Herbomez M, Gouze V (2002). [Chromogranin A: a marker of neuroendocrine tumors]. Ann Biol Clin (Paris) 60(6): 641–6

    CAS  Google Scholar 

  35. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. (1997). Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82(8): 2622–8

    Article  PubMed  CAS  Google Scholar 

  36. Walenta S, Mueller-Klieser WF (2004). Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 14(3): 267–74

    Article  PubMed  Google Scholar 

  37. Paesmans M, Sculier JP, Lecomte J, et al. (2000). Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89(3): 523–33

    Article  PubMed  CAS  Google Scholar 

  38. Ansell SM, Armitage J (2005). Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80(8): 1087–97

    Article  PubMed  CAS  Google Scholar 

  39. Oesterling JE, Martin SK, Bergstralh EJ, et al. (1993). The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269(1): 57–60

    Article  PubMed  CAS  Google Scholar 

  40. Hammerer PG, Kattan MW, Mottet N et al. (2006). Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU Int 98(1): 11–9

    Article  PubMed  Google Scholar 

  41. Kattan MW, Wheeler TM, Scardino PT (1999). Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17(5): 1499–507

    PubMed  CAS  Google Scholar 

  42. Scher HI, Eisenberger M, D’Amico AV, et al. (2004). Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22(3): 537–56

    Article  PubMed  Google Scholar 

  43. D’Amico AV, Moul JW, Carroll PR, et al. (2003). Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95(18): 1376–83

    Google Scholar 

  44. Bonner JA, Sloan JA, Rowland KM Jr,et al. (2000). Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res 6(2): 597–601

    PubMed  CAS  Google Scholar 

  45. Carney DN, Marangos PJ, Ihde DC, et al. (1982). Serum neuronspecific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1(8272): 583–5

    Article  PubMed  CAS  Google Scholar 

  46. Jorgensen LG, Osterlind K, Genolla J, et al. (1996). Serum neuronspecific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 74(3): 463–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncologie médicale, Centre Hospitalier Lyon-Sud, Hospices civils de Lyon et EA 3738, Faculté de médecine de Lyon-Sud, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France

    B. You

Authors
  1. B. You
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. You.

Rights and permissions

Reprints and permissions

About this article

Cite this article

You, B. Quels marqueurs circulants pour quels cancers?. Bio trib. mag. 23, 23–31 (2007). https://doi.org/10.1007/s11834-007-0019-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11834-007-0019-0

Mots clés

Keywords

Search

Navigation